1. Home
  2. TXMD vs NRSN Comparison

TXMD vs NRSN Comparison

Compare TXMD & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TherapeuticsMD Inc.

TXMD

TherapeuticsMD Inc.

HOLD

Current Price

$2.18

Market Cap

24.3M

Sector

Health Care

ML Signal

HOLD

Logo NeuroSense Therapeutics Ltd.

NRSN

NeuroSense Therapeutics Ltd.

HOLD

Current Price

$0.71

Market Cap

28.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TXMD
NRSN
Founded
2008
2017
Country
United States
Israel
Employees
N/A
15
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.3M
28.4M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
TXMD
NRSN
Price
$2.18
$0.71
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
19.6K
180.0K
Earning Date
05-12-2026
03-20-2026
Dividend Yield
N/A
N/A
EPS Growth
80.61
N/A
EPS
N/A
N/A
Revenue
$1,761,000.00
N/A
Revenue This Year
$427.09
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$90.64
N/A
Revenue Growth
35.25
N/A
52 Week Low
$0.84
$0.63
52 Week High
$2.95
$2.60

Technical Indicators

Market Signals
Indicator
TXMD
NRSN
Relative Strength Index (RSI) 37.04 42.79
Support Level $1.05 $0.68
Resistance Level $2.35 $1.30
Average True Range (ATR) 0.11 0.08
MACD -0.02 -0.00
Stochastic Oscillator 2.67 33.55

Price Performance

Historical Comparison
TXMD
NRSN

About TXMD TherapeuticsMD Inc.

TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Share on Social Networks: